Virally targeted therapies for EBV-associated malignancies. - Wikidata - wikimedia - TriplyDB

Virally targeted therapies for EBV-associated malignancies.

Virally targeted therapies for EBV-associated malignancies.

http://www.wikidata.org/entity/Q35196601

about

Regulation of the latent-lytic switch in Epstein-Barr virus Control of Kaposi's sarcoma-associated herpesvirus reactivation induced by multiple signals Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus.Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy Role of the ubiquitin system and tumor viruses in AIDS-related cancer.Evaluation of a prediction protocol to identify potential targets of epigenetic reprogramming by the cancer associated Epstein Barr virus Kleemeier Award Lecture 2008--the canary in the coal mine: telomeres and human healthspan.The Methylation Status and Expression of Epstein-Barr Virus Early Genes BARF1 and BHRF1 in Epstein-Barr Virus-Associated Gastric Carcinomas.LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo Histone deacetylase inhibitors in Hodgkin lymphoma.Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi.Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies Emerging therapies for herpes viral infections (types 1 - 8).Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma.Evidence that amphotericin B mediates reactivation of latent Epstein-Barr virus in Hodgkin's lymphoma allowing cytotoxicity by acyclovir Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa.Bendamustine reactivates latent Epstein-Barr virus.Laboratory assays for Epstein-Barr virus-related disease.CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology.Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer.Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.Multiple infections and cancer: implications in epidemiology.Epigenetic Pathways of Oncogenic Viruses: Therapeutic Promises.(-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma.Treatment of Akata EBV-positive cells with doxorubicin causes more EBV reactivation than treatment with etoposide.Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization.Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors Small molecule perturbation of the CAND1-Cullin1-ubiquitin cycle stabilizes p53 and triggers Epstein-Barr virus reactivation.Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels.Unexpected structure of Epstein-Barr virus lytic cycle activator Zta.Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.

P2860

Q27021366-3F93ED6C-4435-41EC-AF4A-AAEEFBE0165C Q28478842-5B2F0F0A-05E9-44A4-8FC5-2F653FA8ABF3 Q33280632-649B81D1-EBD0-4319-BF07-67AB5A94BEDF Q33289956-580F7D31-B4E4-4449-A3D8-651F6E0AF50F Q33307881-67281274-DBD5-44D3-9A5C-9E334CA531DD Q33535848-3DB6D0D6-8089-44A1-A1A9-1B468CA55CE4 Q33567625-386BC71E-042E-450C-BC4C-B94D93D88F36 Q33604804-08B9D027-AE59-4BE1-AEFA-8EF7CC79C9A4 Q33655676-8E420B76-6F41-48F3-9BE0-082B246B382B Q33755168-08EADD2E-811C-4032-AD25-958205AC45A6 Q34414440-3DAF65D4-3296-4DE7-A130-76663EF05665 Q34520470-E7A9E4B7-E96E-4E86-8CC1-5EFC7FFC8F43 Q34767204-0B980003-A668-4F68-8AF5-69D5E5335B05 Q35690817-9A268295-1625-4C28-9726-913118A8923F Q35733719-728FA1AA-49E5-49A2-8C7E-B8A7D5B6D6B8 Q35795380-74E89282-3B67-49F0-9C15-689D9263C9EE Q35829978-C666CA0B-D879-46E2-926E-5EE5D526CC16 Q35967376-4DB9A7A5-748A-4D11-87EC-4D10CC2A1FCC Q36334405-57EE67A9-5028-4479-90CC-65285B6A90A8 Q36461784-302434E4-5E72-412B-B1DC-D82DEB2AE399 Q36503818-9385512E-B433-4A3E-95AF-8767F90AE945 Q37094781-8E3A2449-658E-4FFC-8D82-1CCDD42F1596 Q37192117-53965FFC-C052-46EE-9BE3-34FFC19B357E Q37261842-4AF8D2AE-8059-4EE0-A23A-FBA4AC0D34D8 Q37773234-9CE80B78-A5C9-4975-B936-30F1B1F4005B Q37849461-425D72D9-1C6C-4F5F-BA00-01D05AFDC98F Q38068839-7C7A7AD7-E789-412F-84A9-C2AF95A364C4 Q38126931-63C8DB62-5BD2-4340-9795-0F7E3AB3C495 Q38692795-D7AA4719-5518-438B-889C-085BF30AEC12 Q39238849-2F8704C6-614D-4421-A8F8-2569A7D53DE7 Q39324686-8CB2885D-97A1-4E6D-98AF-952D5973AE36 Q39548607-6A0BB21B-ED34-4E2D-879C-EC7AFD3A5C37 Q39575256-113F7250-2666-40CD-ABC5-D0CD9E8EB782 Q39735571-A90FD4AE-E983-4702-A445-C3AB3F77F15E Q39749474-09AF948F-C4E9-47C4-BB57-AB4A293B3A1C Q39778922-65C659C4-D353-4BD6-90D7-C5B12A05C7F6 Q40120026-5D317A9B-048D-438D-8F51-CFD4CEFEEDA2 Q40793262-B8B58389-7F19-474D-AF06-46AB1D83D052 Q42160761-9C2A3C71-D953-4C3A-B2F2-80F24F1E06E2 Q45360289-485492D3-0036-4239-B9F9-DBE451F07586

P2860

Virally targeted therapies for EBV-associated malignancies.

http://www.wikidata.org/entity/Q35196601

description

2003 nî lūn-bûn

@nan

2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Virally targeted therapies for EBV-associated malignancies.

@ast

Virally targeted therapies for EBV-associated malignancies.

@en

type

label

Virally targeted therapies for EBV-associated malignancies.

@ast

Virally targeted therapies for EBV-associated malignancies.

@en

prefLabel

Virally targeted therapies for EBV-associated malignancies.

@ast

Virally targeted therapies for EBV-associated malignancies.

@en

P1433

Q35196601-34391F3C-59EB-4AC0-9AF6-A99C1FBC3DB7

P1476

Q35196601-DEDD88B5-3C12-41E6-8D96-AB5099751904

P2093

Q35196601-3FC5588C-7D29-4D96-BD81-0972D07B6405

Q35196601-5618AD8B-C754-4C3C-B30E-53023993F586

P2860

Q35196601-063540B0-8FBC-4E43-85AB-99DCB1A7D5E5

Q35196601-0922A607-95D7-4108-999F-B731AB047788

Q35196601-0BC30BD3-EFB7-4D86-900B-CC41064F8EFC

Q35196601-1FDD8ECD-0649-4AEC-9308-AEE5DFBF5543

Q35196601-22246591-9E43-4956-A923-71822E051028

Q35196601-2A920EC9-8C51-49BD-B4BA-E6BC84233BB5

Q35196601-43B25945-C380-4721-AC93-7A485F3879EE

Q35196601-44A4A948-2106-4743-90BE-71B7948A7BA4

Q35196601-4670A500-4E1A-431E-9F4F-0842740DAC5D

Q35196601-479C8583-7080-4B93-A7C4-90195A9C20DF

P2888

Q35196601-DE7868E4-EA60-4301-B658-7FD2B022A5B4

P304

Q35196601-A0120B56-EDF1-41C3-ABF3-224CF663C75E

P31

Q35196601-6578BB22-0737-4CB3-9AE2-26922445E7D1

P356

Q35196601-BA88E754-B619-4875-B8A4-6AA76098C37B

P407

Q35196601-EE7288B3-BA45-4187-ABDC-AD587BAE038A

P433

Q35196601-21487AC7-E0FB-4F9A-ADF1-377B661B7F3E

P478

Q35196601-132B4D60-7096-430D-B4AB-776098CA671C

P577

Q35196601-A41C1A0A-9A3A-4BA1-B28B-D1819FD08D88

P5875

Q35196601-5F3BE1EE-CCDD-4AEA-B424-90E0C2659F87

P6179

Q35196601-5618ABE8-DB99-4E46-B3DA-5C19FFF609D4

P698

Q35196601-2F3E34C5-144F-4331-8581-542C700E1B8B

P356

P1433

P1476

Virally targeted therapies for EBV-associated malignancies.

@en

P2093

Bruce F Israel

http://www.w3.org/2001/XMLSchema#string

Shannon C Kenney

http://www.w3.org/2001/XMLSchema#string

P2860

NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells

Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency

Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases

Histone acetylation and reactivation of Epstein-Barr virus from latency.

Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus

Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.

Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues

Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.

Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation.

P2888

P304

5122-5130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1206548

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10620527

http://www.w3.org/2001/XMLSchema#string

P6179

1040757147

http://www.w3.org/2001/XMLSchema#string

P698

12910249

http://www.w3.org/2001/XMLSchema#string